Wockhardt inks pact for dermatology drug with UK's LSI
Mumbai, June 5 (UNI) Wockhardt has tied-yup with UK-based dermatology products company, LSI, to market Vitix, a patented product for the treatment of pigmentation disorder - vitiligo.
''The agreement is part of the Wockhardt's initiative to bring new advances in medicine to India,'' a company release said quoting its Chairman Habil Khorakiwala. ''We plan to expand our portfolio in cardiology, diabetology and dermatology by introducing new products that have proved their effectiveness in other parts of the world,'' he said.
Vitiligo, popularly called leucoderma, is a skin disorder affecting one to two per cent of global population in which the patient develops white patches caused by localised loss of pigment. These white patches are liable to sun burn.
Vitix, a gel for topical application, will be manufactured by the company in India from active pharmaceutical ingredients (API) imported from LSI. Vitix is expected to be launched in India in the last quarter this year. It offers advantages like fast onset of action and high success rate with established safety. Vitix is now marketed in Europe, North America, South East Asia and Africa.
UNI SN GK NV1651